Savelyev University Surgical Clinic, Pirogov Russian National Research Medical University, Moscow, Russia.
Phlebology. 2024 Sep;39(8):534-542. doi: 10.1177/02683555241256264. Epub 2024 May 20.
To assess the incidence of pelvic vein thrombosis (PVT) and outcomes of anticoagulant therapy for PVT in patients with pelvic venous disorders (PeVDs).
This prospective cohort study included 588 female patients with PeVDs underwent clinical examination followed by duplex ultrasound of the pelvic veins in 2021-2023. Patients with PVT were administered with anticoagulant therapy in an outpatient setting using low molecular weight heparins at a therapeutic dose.
PVT was detected in 7.6% of patients with PeVDs and was symptomatic in 28.8% of them. The majority of asymptomatic patients had thrombosis in only one of the parametrial veins (90.6%). Anticoagulant therapy resulted in the PVT symptoms relief in all patients within 10 days and recanalization of the pelvic veins in 1-3 months.
In our study, PVT was diagnosed in 7.6% of patients with PeVDs. Anticoagulant therapy is effective and safe in resolving PVT symptoms.
评估盆腔静脉疾病（PeVDs）患者中盆腔静脉血栓形成（PVT）的发生率和抗凝治疗 PVT 的结局。
本前瞻性队列研究纳入了 2021 年至 2023 年间接受临床检查和盆腔静脉双功能超声检查的 588 例女性 PeVDs 患者。对有 PVT 的患者在门诊进行抗凝治疗，使用低分子肝素进行治疗剂量。
PeVDs 患者中有 7.6%发现 PVT，其中 28.8%有症状。大多数无症状患者仅在一条旁静脉中有血栓（90.6%）。抗凝治疗在 10 天内使所有患者的 PVT 症状得到缓解，在 1-3 个月内盆腔静脉再通。
在我们的研究中，PeVDs 患者中有 7.6%诊断为 PVT。抗凝治疗在缓解 PVT 症状方面是有效和安全的。
